Daré Bioscience, Inc. — Form 8-K Summary
Business context and reporting period
Filed October 2, 2026, reporting an event dated September 28, 2026. This is a Nasdaq listing-status notice, not a periodic financial report.
Financial information
The filing provides no revenue, earnings, cash flow, margin, debt, liquidity, or other financial results.
Material event and outlook
Daré received notice that its common stock closing bid price had been below Nasdaq’s $1.00 minimum for 30 consecutive business days. The notice has no immediate effect on the stock’s Nasdaq Capital Market listing. The company has until March 29, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days, subject to Nasdaq’s discretion.
If Daré does not meet the requirement by that date, it may qualify for an additional 180-day compliance period if it satisfies other applicable listing standards and notifies Nasdaq of its intent to cure the deficiency, potentially through a reverse stock split. Otherwise, Nasdaq may issue a delisting notice, which Daré could appeal to a Nasdaq Hearing Panel. The company said it will monitor the bid price and consider compliance options; it gave no assurance that it will regain or maintain compliance.
Key facts for investors to verify
- Whether Daré regains the $1.00 minimum bid-price compliance by March 29, 2027.
- Whether the company qualifies for an additional compliance period and whether it pursues a reverse stock split.
- Any subsequent Nasdaq notice, delisting determination, or appeal.